Samsung Biologics
207940.KS
$1,258
Share price
-1.21%
Change (1 day)
22.19%
Change (1 year)
Categories
Revenue for Samsung Biologics (207940.KS)
Revenue in 2024 (TTM): NZ$5.50 Billion
According to Samsung Biologics
's latest financial reports the company's current revenue (TTM 
) is NZ$5.75 Billion. an increase over the revenue in the year 2023 that were of NZ$4.43 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Samsung Biologics from 2016 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | NZ$5.86 B | 32.1% |
| 2023 | NZ$4.43 B | 22.51% |
| 2022 | NZ$3.62 B | 83.5% |
| 2021 | NZ$1.97 B | 41.43% |
| 2020 | NZ$1.39 B | 55.94% |
| 2019 | NZ$0.89 B | 23.27% |
| 2018 | NZ$0.72 B | 23.07% |
| 2017 | NZ$0.58 B | 60.48% |
| 2016 | NZ$0.36 B |